Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ECOR vs DARE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DARE Captures Overall Composite Edge (43.1 HOLD vs 56.8 HOLD), While ECOR Leads 3–1 on Growth & Valuation Pillars

DARE Overall Winner 6-Pillar Tally: ECOR 3 – 1 DARE (2 Tie) Matrix Metrics: ECOR 4 – 6 DARE

As of Nov 19, 2026, Dare Bioscience, Inc. (DARE) captures the overall head-to-head institutional edge over electroCore, Inc. (ECOR) on higher Unified Composite conviction (43.1/100 HOLD vs. 56.8/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples), while ECOR wins 3–1 across the 6-pillar growth and valuation breakdown. ECOR trades at $4.85 (N/M Forward P/E, -33.1% operating margin) versus DARE at $0.45 (1.3x Forward P/E, -746.1% operating margin).

  • Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. DARE 43.1/100 HOLD), DARE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (-746.1% vs. -33.1% operating margin) and revenue trajectory (+2005.6% vs. +11.5% YoY).
  • Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile DARE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ECOR vs DARE
ECOR NASDAQ
electroCore, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.85
-6.19% 1D
Market Cap $47.7M
TTM Revenue $38M
Forward P/E N/M
Beta / 30D Vol 1.52β · 155% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 68.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.5%), weak momentum, RSI 32
RSI-14: 31.5 · SMA20: $6.90 · SMA50: $8.67
DARE NASDAQ Head-to-Head Winner
Dare Bioscience, Inc. Common Stock
Pharmaceutical Preparations
$0.45
+0.44% 1D
Market Cap $8.8M
TTM Revenue $1.4M
Forward P/E 1.3x
Beta / 30D Vol 1.52β · 112% Vol
Unified Composite Score
43.1 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.0%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $0.63 · SMA50: $0.71

6-Pillar Scorecard Institutional Category Breakdown (ECOR 3 – 1 DARE)

Columns: Metric · ECOR · DARE
1. Valuation Multiples DARE
Forward P/E N/M 1.3x
Trailing P/E N/M 1.3x
PEG Ratio N/M N/M
EV / Revenue 1.4x N/M
2. Growth & Scale ECOR
Revenue Growth (YoY) +11.5% +2005.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $38M $1.4M
Market Cap $47.7M $8.8M
3. Profitability & Quality ECOR
Gross Margin 87.7% N/A
Operating Margin -33.1% -746.1%
Net Profit Margin -33.5% 0.0%
Return on Equity (ROE) -478.7% -407.1%
4. Balance Sheet & Cash Flow ECOR
Cash Generation (TTM) -$6.9M -$12M
Cash Flow Margin -18.1% N/A
Net Cash / Leverage $4.6M Net Debt $12M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ECOR (4) vs DARE (6)
Institutional Metric ECOR DARE Criterion Row Edge
Market Capitalization
Scale
$47.7M $8.8M Larger Scale ECOR
Trailing P/E Ratio
Valuation
N/M 1.3x Lower Multiple DARE
Forward P/E Ratio
Valuation
N/M 1.3x Lower Multiple DARE
Revenue Growth (YoY)
Growth
+11.5% +2005.6% Higher Growth DARE
Operating Margin (TTM)
Profitability
-33.1% -746.1% Higher Margin ECOR
Net Profit Margin
Profitability
-33.5% 0.0% Higher Margin DARE
Return on Equity (ROE)
Capital Efficiency
-478.7% -407.1% Higher ROE DARE
52-Week Range Position
Momentum
6% ($4–$13) 1% ($0–$4) Stronger Trend ECOR
Beta / 30D Volatility
Risk Regime
1.52β · 155% Vol 1.52β · 112% Vol Lower Realized Risk DARE
Unified Institutional Score
Composite Signal
56.8 / 100 (HOLD) 43.1 / 100 (HOLD) Higher Composite ECOR
Trailing 12M Revenue (USD)
Operating Scale
$38M $1.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.9M ($4.6M Net Debt) -$12M ($12M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ECOR +0.29 pp
ECOR: -34.01% · DARE: -34.3%
3M Horizon DARE +9.03 pp
ECOR: -53.9% · DARE: -44.87%
6M Horizon ECOR +62.21 pp
ECOR: -19.03% · DARE: -81.24%
1Y Horizon ECOR +70.65 pp
ECOR: -3.96% · DARE: -74.61%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ECOR Revenue DARE Revenue ECOR Op. Margin DARE Op. Margin Margin Leader
FY2018 $0M N/A -5494.1% N/A ECOR
FY2019 $0M N/A -1928.2% N/A ECOR
FY2020 $0M N/A -707.9% N/A ECOR
FY2021 $10M N/A -367.7% N/A ECOR
FY2022 $10M $10M -266.2% -313.9% ECOR
FY2023 $20M $0M -120.2% -1101.9% ECOR
FY2024 $30M $0M -48.3% -239692.2% ECOR
FY2025 $30M $0M -41.1% -1315.5% ECOR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ECOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DARE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DARE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ECOR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $47.7M market capitalization and -33.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DARE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $8.8M market capitalization and -746.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ECOR vs DARE Key Questions & Quantitative Answers

As of Nov 19, 2026, Dare Bioscience, Inc. (DARE) captures the overall head-to-head institutional edge over electroCore, Inc. (ECOR) on higher Unified Composite conviction (43.1/100 HOLD vs. 56.8/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples), while ECOR wins 3–1 across the 6-pillar growth and valuation breakdown. ECOR trades at $4.85 (N/M Forward P/E, -33.1% operating margin) versus DARE at $0.45 (1.3x Forward P/E, -746.1% operating margin). Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. DARE 43.1/100 HOLD), DARE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (-746.1% vs. -33.1% operating margin) and revenue trajectory (+2005.6% vs. +11.5% YoY). Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile DARE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ECOR leads the Growth & Scale pillar: ECOR posts +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin), compared with DARE at +2005.6% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (N/A gross margin, -746.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ECOR cumulative revenue shifted +200.0% while DARE shifted N/A. In operating R&D and SG&A reinvestment, ECOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DARE.

DARE screens cheaper on headline valuation multiples. ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-18.1% FCF margin), whereas DARE trades at 1.3x Forward P/E, 1.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECOR (-478.7% ROE) versus DARE (-407.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 155% Vol realized risk). By comparison, DARE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 112% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.